Brett Smith for redOrbit.com - Your Universe Online Studies have shown that forgetfulness as we get older can be seen in the form of neurons in our brains beginning to fray and disappear. Now, a new study published in Proceedings of the...
Latest Riluzole Stories
ReportsnReports.com adds “OpportunityAnalyzer Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018” to its store.
Transparency Market Research Report Added "Amyotrophic Lateral Sclerosis Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database.
Keck School of Medicine of USC neuroscientists have unlocked a piece of the puzzle in the fight against Lou Gehrig's disease, a debilitating neurological disorder that robs people of their motor skills.
There is no specific drug to treat spinal muscular atrophy (SMA), a family of motor neuron diseases that in its most severe form is the leading genetic cause of infant death in the United States and affects one in 6,000 people overall.
ANN ARBOR, Mich., June 23, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc.
Pediatric-onset obsessive compulsive disorder (OCD) and Tourette's disorder (TD) share similarities in their underlying genetic and environmental factors, psychiatric features, and treatment methods.
A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS), scientists report after completing a Phase II clinical trialâ€”an early, small-scale test to show if the drug works and continues to be safe.
A medication used to ease symptoms of amyotrophic lateral sclerosis, or Lou Gehrig's disease, also is helpful in treating people with treatment-resistant obsessive-compulsive disorder (OCD), according to a pilot study at Yale School of Medicine.
- The act of sweetening by admixture of some saccharine substance.